SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the public of $17.00 per share.

圣迭戈，2026年9月24日（环球电讯社）——ADARx Pharmaceuticals, Inc.（ADARx），一家致力于开发下一代siRNA疗法的后期临床生物技术公司，今日宣布其扩大规模的首次公开募股（IPO）的定价：以每股17.00美元的公开发行价格，发行26,250,000股普通股。

All of the shares of common stock are being offered by ADARx. The gross proceeds to ADARx from the offering, before deducting underwriting discounts and commissions and offering expenses payable by ADARx, are expected to be approximately $446.3 million. In addition, the underwriters have a 30-day option to purchase up to an additional 3,937,500 shares of common stock at the public offering price, less underwriting discounts and commissions..

ADARx 正在发售其全部普通股。在扣除承销折扣、佣金以及由 ADARx 支付的发行费用之前，ADARx 从本次发行中获得的总收益预计约为 4.463 亿美元。此外，承销商拥有 30 天的选择权，可按公开发行价格（减去承销折扣和佣金）额外购买最多 3,937,500 股普通股。

The shares are expected to begin trading on The Nasdaq Global Select Market on September 25, 2026, under the ticker symbol “ADRX.” The offering is expected to close on September 28, 2026, subject to the satisfaction of customary closing conditions.

预计该股票将于2026年9月25日在纳斯达克全球精选市场开始交易，股票代码为“ADRX”。本次发行预计将于2026年9月28日完成，前提是满足惯常的交割条件。

J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are acting as lead book-running managers for the offering. LifeSci Capital is acting as a book-running manager for the offering.

摩根大通、摩根士丹利、TD Cowen 和瑞银投资银行担任本次发行的牵头账簿管理人。LifeSci Capital 担任本次发行的账簿管理人。

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 24, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities.

与这些证券相关的注册声明已提交至美国证券交易委员会（SEC），并于2026年9月24日生效。注册声明的副本可通过美国证券交易委员会网站www.sec.gov获取。本次发行仅通过构成与这些证券相关的注册声明一部分的招股说明书进行。

When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co.

如有提供，与首次公开发行相关的最终招股说明书副本可从以下地址获取：J.P. Morgan Securities LLC，转交 Broadridge Financial Solutions，地址为纽约州埃奇伍德长岛大道 1155 号，邮编 11717；或通过电子邮件发送至 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；Morgan Stanley & Co.

LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by email at prospectus@morganstanley.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or UBS Securities LLC, Attention: Equity Syndicate, 11 Madison Avenue, New York, NY 10010 or by email at ol-prospectus-request@ubs.com..

有限责任公司，收件人：招股说明书部门，地址：纽约州纽约市瓦里克街180号2楼，邮编10014，电话：1-866-718-1649，电子邮件：prospectus@morganstanley.com；TD证券（美国）有限责任公司，转交Broadridge金融解决方案公司，地址：纽约州埃奇伍德长岛大道1155号，邮编11717，电子邮件：TDManualrequest@broadridge.com；或瑞银证券有限责任公司，收件人：股票承销团，地址：纽约州纽约市麦迪逊大道11号，邮编10010，电子邮件：ol-prospectus-request@ubs.com。

In addition, AbbVie has agreed to purchase, in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), a number of shares of ADARx’s common stock that would result in AbbVie owning approximately 4.9% of ADARx’s outstanding shares of common stock following the closing of the initial public offering and the concurrent private placement, at a price of $17.00 per share; provided, however, that in no event would AbbVie purchase more than $100.0 million in shares of common stock.

此外，艾伯维已同意在一次免于遵守经修订的《1933年证券法》（以下简称“《证券法》”）注册要求的同步私募配售中，以每股17.00美元的价格购买一定数量的ADARx普通股，使得在首次公开发行及同步私募配售完成后，艾伯维将持有ADARx已发行普通股的大约4.9%；但无论如何，艾伯维购买的普通股总金额不超过1亿美元。

The aggregate gross proceeds to ADARx from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions, placement agent fees and other offering and private placement expenses payable by ADARx, are expected to be approximately $535.2 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock.

在不扣除由ADARx支付的承销折扣和佣金、配售代理费以及其他发行和私募费用的情况下，ADARx从首次公开募股及同步进行的私募配售中获得的总募集资金总额预计约为5.352亿美元，此金额未包含承销商行使额外购买普通股选择权的任何情况。

The concurrent private placement is also scheduled to close on September 28, 2026, subject to the satisfaction of customary closing conditions. The closing of the concurrent private placement is contingent and conditioned upon consummation of the initial public offering. However, the closing of the initial public offering is not contingent on the consummation of the concurrent private placement..

同步进行的私募配售也计划于2026年9月28日完成，但须满足惯常的交割条件。同步私募配售的交割以首次公开发行的完成为前提条件。然而，首次公开发行的交割并不以同步私募配售的完成为条件。

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约，也不构成购买这些证券的要约邀请；在任何州或司法管辖区，若在此类证券根据该州或司法管辖区的证券法进行注册或资格认定之前，此类要约、邀请或销售行为属违法，则不得在该州或司法管辖区销售这些证券。

Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act..

任何要约、招揽或购买要约，或任何证券销售，均将根据《证券法》的注册要求进行。

About ADARx Pharmaceuticals

关于 ADARx 制药公司

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. We have developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs.

ADARx Pharmaceuticals, Inc. 是一家处于后期阶段的生物技术公司，致力于将前沿科学转化为下一代小干扰RNA（siRNA）疗法。我们开发了旨在通过高度选择性的RNA靶向疗法控制特定疾病驱动因子表达的技术，目标是为存在未满足医疗需求的患者提供改变生命的治疗方案。

ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases.

ADARx 致力于推进和拓展其深厚的研发管线，开发高效、持久且选择性强的 RNA 靶向治疗候选药物，针对补体介导疾病、遗传性疾病、心血管疾病、血栓形成、中枢神经系统疾病以及代谢性疾病（肥胖症）开发产品候选药物。

In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology..

除了我们全资拥有的项目外，我们还与艾伯维（AbbVie）达成了一项合作及许可选择权协议，以开发针对包括神经科学、免疫学和肿瘤学在内的多个疾病领域的小干扰RNA（siRNA）疗法。

Forward-Looking Statements

前瞻性陈述

The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as “believe,” “can,” “estimate,” “expect,” “intend,” “may,” “plans,” “should,” “seeks,” or “will,” or similar expressions which concern ADARx’s strategy, plans, projections or intentions.

本新闻稿中非历史事实的陈述均为前瞻性陈述。您可以通过其中包含的诸如“相信”、“能够”、“估计”、“预期”、“打算”、“可能”、“计划”、“应该”、“寻求”或“将”等词语，或涉及 ADARx 战略、计划、预测或意图的类似表述来识别前瞻性陈述。

These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to ADARx’s expected gross proceeds from the initial public offering and concurrent private placement, the expected date for ADARx’s common stock to begin trading on the Nasdaq Global Select Market and the expected closing of the initial public offering and concurrent private placement.

这些前瞻性陈述可能包含在本新闻稿的各个部分，包括但不限于有关ADARx公司从首次公开募股及同步私募配售中预期获得的总收益、其普通股在纳斯达克全球精选市场开始交易的预期日期，以及首次公开募股和同步私募配售的预期完成时间的陈述。

By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. ADARx’s expectations, beliefs and projections are expressed in good faith and ADARx believes there is a reasonable basis for them.

前瞻性陈述就其性质而言，并非对历史事实的陈述或对未来表现的保证，而是受到难以预测或量化的风险、不确定性、假设或情况变化的影响。ADARx 的预期、信念和预测均本着诚信原则作出，且 ADARx 认为这些预期、信念和预测具有合理依据。

However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release.

然而，无法保证管理层的预期、信念和预测能够实现或达成，实际结果可能与前瞻性陈述中表达或暗示的内容存在重大差异。本新闻稿中的任何前瞻性陈述仅截至本新闻稿发布之日有效。

ADARx undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws..

ADARx 不承担任何义务公开更新或审查任何前瞻性陈述，无论是由于新信息、未来发展还是其他原因，除非适用的证券法律另有要求。